Importantly, preclinical studies have validated WEE1 inhibition as a viable therapeutic target in treating cancer [117], and CDC25A is also deemed as a suitable therapeutic target for cancer treatment [118], establishing βTrCP as a tumor suppressor. Here, CDC25A is linked to cancer.